NUCLIDIUM

About NUCLIDIUM

Nuclidium AG is a clinical-stage biotechnology company focused on pioneering next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer. Utilizing copper isotopes (Copper-61 for diagnostics and Copper-67 for therapeutics), they aim to create a differentiated platform to overcome limitations in radiotheranostics, delivering scalable, accessible, and clinically superior theranostic solutions worldwide.

Products & Services

Copper-based Radiopharmaceuticals:Next-generation radiotherapeutics using Copper-61 for diagnostics and Copper-67 for therapeutics, aimed at precision oncology.

CuTrace™ Platform:A proprietary platform enabling flexible development of radiotherapeutics with companion diagnostics for targeted cancer treatment.

Copper-61 diagnostics

Copper-67 therapeutics

copper-based radiopharmaceuticals

Specialties

Copper-based Radiopharmaceuticals Precision Oncology Radiotheranostics Cancer Diagnosis and Treatment precision oncology radiotheranostics targeted cancer treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 26400000 MR: - FA: CHF 26.4 million (extension); total Series B CHF 105 million FAN: 26400000	D: 2026-05-27 FD: 2026-05-27	9 investors
2	RT: Series B T: - FT: Series B	A: 86900000 MR: - FA: CHF 79 million (EUR 84 million) FAN: 86900000	D: 2025-07-10 FD: 2025-07-10	11 investors
3	RT: Series B T: - FT: Series B	A: 85000000 MR: - FA: CHF 79 Million (EUR 84 Million) FAN: 85000000	D: 2025-07-10 FD: 2025-07-10	11 investors

Series B Latest

2026-05-27

$26.4M

9 investors (Pro only)

Series B 2025-07-10

$86.9M

Series B 2025-07-10

$85.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Tony Rosenberg

Chairman

L

Leila Jaafar-Thiel

CEO & Founder

R

Regina Hodits

Managing Director at Angelini Ventures

D

David Meek

Independent Director

L

Liliana Nordbakk

Partner Life Sciences at Neva SGR

D

Daniel Parera

Partner at Kurma Partners

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

NUCLIDIUM Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised